ArticleAnnals of translational medicine2022
Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Co-Culture of nasopharyngeal carcinoma cells and fibroblasts induces altered integrin expression associated with 3D structural formation.Cytotechnology · 2026Article
- Research Advances and Disease Modeling in Respiratory Organoids.Biomedicines · 2026Review
- Synergistic carcinogenesis of the nasopharyngeal microbiome and Epstein-Barr virus: mechanisms of metabolic reprogramming and immune evasion.Frontiers in immunology · 2026Review
- Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation.Stem cell research & therapy · 2025Review
- Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives.Journal of personalized medicine · 2025Review
- Innovative organ-on-a-chip platforms for exploring tumorigenesis and therapy in head and neck cancer.Journal of translational medicine · 2025Review
- Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025Review
- Article
- Spatially defined microenvironment for engineering organoids.Biophysics reviews · 2024Review
- Living Biobanks of Organoids: Valuable Resource for Translational Research.Biopreservation and biobanking · 2024Review
- [Development of a new platform for testing antiviral drugs using coronavirus-infected human nasal mucosa organoids].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Applications and perspectives of tumor organoids in radiobiology (Review).Oncology reports · 2024Review
- Application of organoids in otolaryngology: head and neck surgery.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Review
- Toward reproducible tumor organoid culture: focusing on primary liver cancer.Frontiers in immunology · 2024Review
- In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.Journal of personalized medicine · 2023Review
- Tumor organoid model of colorectal cancer (Review).Oncology letters · 2023Review
- Tumor organoid biobank-new platform for medical research.Scientific reports · 2023Article
- Targeted therapy for head and neck cancer: signaling pathways and clinical studies.Signal transduction and targeted therapy · 2023Review
- The applications and techniques of organoids in head and neck cancer therapy.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent nasopharyngeal carcinoma (NPC) remains a major challenge for clinicians and scientists. Tumor organoid is a revelational disease model that highly resembled the heterogeneity and histopathological characteristics of original tumors. This study aimed to optimize the modeling process of patient-derived NPC organoids (NPCOs), and establish a living-biobank of NPCs to study the mechanism and explore the more effective treatment of the disease. Methods: Sixty-two fresh NPC tissue samples and 15 normal mucosa samples were collected for 3-dimensional (3D) organoid culture. The organoids were confirmed using hematoxylin and eosin assays. The expression levels of Results: We identified a novel two-step enzymatic strategy for the treatment of NPC and nasal mucosa specimens and an optimal medium for culturing NPCOs and nasal mucosa organoids (NMOs). Organoid cultures were generated from 34 primary NPC samples, 28 recurrent NPC samples, and 15 normal mucosa samples. The success rates for primary NPCO, recurrent NPCO, and NMO formation were 47.06%, 81.25%, and 86.5%, respectively. All the NPCOs were Conclusions: In summary, we successfully established a living biobank using the NPCO model, which has enormous potential in basic and clinical research on NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.